5 completed, 2 terminated, 2 unknown, 1 active not recruiting. 6 Phase 2, 4 Phase 3, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 4 | Completed 2, Terminated 2 |
| Early Phase 1 | 1 | Withdrawn 1 |
| Not applicable | 1 | Completed 1 |
Follow Scleroderma, Limited: new trials by email Literature Review of Scleroderma, Limited trials Research Report on Scleroderma, Limited
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis Nemolizumab, Placebo - Systemic Sclerosis | Phase 2 | Recruiting | Galderma R&D | 162 | 2026-02-20 | 2026-03-31 |
| Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot) Mycophenolate Mofetil 500mg - Systemic Sclerosis, Limited Cutaneous Systemic Sclerosis | Phase 2 | Unknown | University College, London | 120 | 2021-12-08 | 2023-07-27 |
| Exercise With Scleroderma Functional Outcomes Exercise Program - Scleroderma, Systemic, Scleroderma, Diffuse | Not applicable | Completed | Trakya University | 44 | 2021-02-05 | 2024-05-22 |
| Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease hyaluronidase injected intradermally - Microstomia, Scleroderma | Early Phase 1 | Withdrawn | Brigham and Women's Hospital | 2020-01-01 | 2021-01-14 | |
| Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon INOMAX - CREST Syndrome, Calcinosis Cutis | Unknown | RoseLab Skin Optics Laboratory | 5 | 2019-06-20 | 2019-06-03 | |
| Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension Oral Ifetroban, Oral Placebo - Scleroderma, Diffuse, Scleroderma, Systemic | Phase 2 | Active not recruiting | Cumberland Pharmaceuticals | 34 | 2017-01-01 | 2026-09-02 |
| Exparel as a Nerve Block for Severe Hand Pain liposomal bupivacaine - CREST Syndrome, Peripheral Vascular Disease | Phase 2 / Phase 3 | Terminated | Jose Soberon, MD | 13 | 2014-11-01 | 2024-05-21 |
| A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma Limited Scleroderma, Diffuse Scleroderma | Completed | Gilead Sciences | 29 | 2013-04-01 | 2014-04-17 | |
| Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis Sildenafil citrate, Placebo (Sugar pill) - Scleroderma, Systemic, Scleroderma, Diffuse | Phase 3 | Completed | Federal University of São Paulo | 41 | 2011-04-01 | 2016-12-05 |
| Tibial Delayed Healing Pivotal Clinical Trial INFUSE/MASTERGRAFT, Autograft bone - Tibial Delayed Healing | Phase 3 | Terminated | Medtronic Spinal and Biologics | 23 | 2010-11-01 | 2015-01-21 |
| Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine treprostinil diethanolamine, placebo - Systemic Sclerosis, Scleroderma | Phase 2 | Completed | United Therapeutics | 148 | 2009-05-01 | 2023-12-28 |
| Effectiveness and Safety of Lidocaine for Scleroderma Lidocaine 2% without vessel constrictor, Placebo - physiological solution 0,9% - Scleroderma | Phase 2 / Phase 3 | Completed | Federal University of São Paulo | 26 | 2004-04-01 | 2008-08-22 |
Scleroderma, Diffuse (9) · Scleroderma, Systemic (6) · CREST Syndrome (3) · Raynaud Disease (3) · Autoimmune Diseases (1) · Calcinosis Cutis (1) · Connective Tissue Diseases (1) · Fractures, Bone (1) · Lung Diseases, Interstitial (1) · Microstomia (1) · Motor Activity (1) · Pathologic Processes (1) · Peripheral Vascular Diseases (1) · Scleroderma, Localized (1)
Skin and Connective Tissue Diseases (12) · Connective Tissue Diseases (11) · Skin Diseases (11) · Scleroderma, Systemic (6) · Cardiovascular Diseases (4) · Embolism and Thrombosis (4) · Livedoid Vasculopathy (4) · Skin Diseases, Vascular (4) · Thrombosis (4) · Vascular Diseases (4) · Calcinosis (3) · Calcium Metabolism Disorders (3) · Deglutition Disorders (3) · Digestive System Diseases (3) · Esophageal Diseases (3)
Endothelium-Dependent Relaxing Factors (1) · Lidocaine (1) · Long-Term Synaptic Depression (1) · Mycophenolic Acid (1) · Resistance Training (1) · Sildenafil Citrate (1) · Sugars (1) · ifetroban (1) · nemolizumab (1) · treprostinil (1)
Federal University of São Paulo (2) · Brigham and Women's Hospital (1) · Cumberland Pharmaceuticals (1) · Galderma R&D (1) · Gilead Sciences (1) · Jose Soberon, MD (1) · Medtronic Spinal and Biologics (1) · RoseLab Skin Optics Laboratory (1) · Trakya University (1) · United Therapeutics (1) · University College, London (1)
United States (5) · Brazil (2) · Canada (2) · United Kingdom (2) · Australia (1) · India (1) · Switzerland (1) · Turkey (Türkiye) (1)
Alexandre WS Silva, PhD (1) · Bittoo Kanwar, MD (1) · Christopher Denton (1) · Evan Brittain, MD (1) · Fernando V Andrigueti, MD (1) · Figen Yargucu Zihni, MD (1) · James Seibold, MD (1) · Jose Soberon, MD (1) · Rachel Riera, MD (1) · Virginia FM Trevisani, PhD (1)
PMID 21312348, PMID 21951278, PMID 24812476, PMID 27384349, PMID 27941129, PMID 29381834, PMID 29667474, PMID 29696997, PMID 30079996, PMID 30318128, PMID 30809542, PMID 31130325, PMID 31216880, PMID 31482431, PMID 31858338, PMID 32062031, PMID 33448431, PMID 34069099, PMID 35234358, PMID 37597472, PMID 37929840, PMID 42421251
2019 (1)